MR Imaging of Relapsing Multiple Sclerosis Patients Using Ultra-Small-Particle Iron Oxide and Compared with Gadolinium

References

1. ↵
   Raivich G, Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Brain Res Rev 2004;46:261–81

   CrossRefPubMed
2. ↵
   Kornek B, Lassmann H. Neuropathology of multiple sclerosis—new concepts. Brain Res Bull 2003;61:321–26

   CrossRefPubMedWeb of Science
3. ↵
   Lucchinetti C, Brück W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 2001;14:259–69

   CrossRefPubMedWeb of Science
4. ↵
   Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938–52

   CrossRefPubMedWeb of Science
5. ↵
   Brück W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788–96

   CrossRefPubMedWeb of Science
6. ↵
   Miller DH, Grossman RI, Reingold SC, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3–24

   Abstract/FREE Full Text
7. ↵
   Filippi M, Grossman RI. MRI techniques to monitor MS evolution. The present and the future. Neurology 2002;58:1147–53

   Abstract/FREE Full Text
8. ↵
   Grossman RI, Braffman BH, Brorson JR, et al. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 1988;169:117–22

   PubMedWeb of Science
9. ↵
   Barnes D, Munro PM, Youl BD, et al. The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain 1991;114:1271–80

   Abstract/FREE Full Text
10. ↵
    Narayana PA, Doyle TJ, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43:56–71

    CrossRefPubMedWeb of Science
11. ↵
    Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI meta-analysis group. Lancet 1999;353:964–69

    CrossRefPubMedWeb of Science
12. ↵
    Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115–21

    CrossRefPubMedWeb of Science
13. ↵
    Dousset V, Delalande C, Ballarino L, et al. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med 1999;41:329–33

    CrossRefPubMedWeb of Science
14. ↵
    Dousset V, Ballarino L, Delalande C, et al. Comparison of ultrasmall particles of iron oxide (USPIO) T2-weighted, conventional T2-weighted and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR Am J Neuroradiol 1999;20:223–27

    Abstract/FREE Full Text
15. ↵
    Rausch M, Hiestand P, Baumann D, et al. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003;50:309–14

    CrossRefPubMedWeb of Science
16. Deloire MS, Touil T, Brochet B, et al. Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult Scler 2004;10:540–48

    Abstract/FREE Full Text
17. ↵
    Floris S, Blezer ELA, Schreibelt G, et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis. A quantitative study. Brain 2004;127:616–27

    Abstract/FREE Full Text
18. ↵
    Pirko I, Johnson A, Ciric B, et al. In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies. FASEB 2004;18:179–81

    Abstract/FREE Full Text
19. ↵
    Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class contrast agents for MR imaging. Radiology 1990;175:494–98

    PubMedWeb of Science
20. Schulze E, Ferrucci JT Jr, Poss K, et al. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest Radiol 1995;30:604–10

    CrossRefPubMed
21. ↵
    Moore A, Weissleder R, Bogdanov A. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997;7:1140–45

    PubMedWeb of Science
22. ↵
    Rausch M, Sauter A, Fröhlich J, et al. Dynamic patterns of USPIO enhancement can be observed in macrophages after ischemic brain damage. Magn Reson Med 2001;46:1018–22

    CrossRefPubMedWeb of Science
23. Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001;103:415–22

    Abstract/FREE Full Text
24. ↵
    Schroeter M, Saleh A, Wiedermann D, et al. Histochemical detection of ultrasmall superparamagnetic iron oxide (USPIO) contrast medium uptake in experimental brain ischemia. Mag Reson Med 2004;52:403–06

    CrossRefPubMedWeb of Science
25. ↵
    Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques to monitor the treatment of multiple sclerosis. Ann Neurol 1996;39:6–16

    CrossRefPubMedWeb of Science
26. ↵
    Dousset V, Gomez C, Petry KG, et al. Dose and scanning delay using USPIO for central nervous system macrophage imaging. MAGMA 1999;8:185–89

    CrossRefPubMed
27. ↵
    Wekerle H. Immunology of multiple sclerosis. In: Compston A, ed. McAlpine’s multiple sclerosis. 3rd ed. London: Churchill Livingstone;1998 :379–407
28. ↵
    Martin R, McFarland H. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995;32:121–82

    CrossRefPubMedWeb of Science
29. ↵
    Genain CP, Canella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170–75

    CrossRefPubMedWeb of Science
30. ↵
    Lucchinetti CF, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions; implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–17

    CrossRefPubMedWeb of Science
31. ↵
    Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469–76

    Abstract/FREE Full Text
32. ↵
    Miki Y, Grossman RI, Udupa JK, et al. Differences between relapsing-remitting and chronic progressive multiple sclerosis as determined with quantitative MR imaging. Radiology 1999;210:769–74

    PubMedWeb of Science
33. ↵
    Enochs WS, Harsh G, Hochberg F, et al. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999;9:228–32

    CrossRefPubMedWeb of Science
34. ↵
    Saleh A, Schroeter M, Jonkmanns C, et al. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004;127:1670–77

    Abstract/FREE Full Text
35. ↵
    Daldrup-Link HE, Rudelius M, Oostendorp RAJ, et al. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology 2003;228:760–67

    PubMed
36. ↵
    Zimmer C, Weissleder R, Poss K, et al. MR imaging of phagocytosis in experimental gliomas. Radiology 1995;197:533–38

    PubMed